A novel tumor-targeting treatment strategy uses energy restriction via co-delivery of albendazole and nanosilver

作     者：Jianming Liang Ruixiang Li Yuwei He Chengli Ling Qi Wang Yongzhuo Huang Jing Qin Weigen Lu Jianxin Wang 

作者机构：Department of Pharmaceutics School of Pharmacy Fudan University & Key Laboratory of Smart Drug Delivery Ministry of Education Shanghai 201203 China Institute of Clinical Pharmacology Guangzhou University of Traditional Chinese Medicine Guangzhou 510006 China Shanghai Institute of Materia Medica Chinese Academy of Sciences 501 Haike Rd. Shanghai201203 China Shanghailnstitute of Pharmaceuticallndustry China State Institute of Pharmaceutical Industry 285 Gebaini Rd. Shanghai201203 China School of Pharmacy Chengdu University of Traditional Chinese Medicine No 1166 Liu TaiAvenue Wenjiang District Chengdu 610072 China 

出 版 物：《Nano Research》 (纳米研究（英文版）)

年 卷 期：2018年第11卷第9期

页      面：4507-4523页

核心收录：

学科分类：0808[工学-电气工程] 0809[工学-电子科学与技术（可授工学、理学学位）] 07[理学] 0805[工学-材料科学与工程（可授工学、理学学位）] 0701[理学-数学] 0702[理学-物理学] 070101[理学-基础数学] 

基　　金：support from the National Natural Science Foundation of China 国家973计划 the Development Project of Shanghai Peak Disciplines - Integrated Medicine 

主　　题：albendazole nano silver co-delivery tumor targeting energy metabolism 

摘      要：Although nanotechnology has been rapidly developed and applied in tumor targeting, the outcome of chemotherapy remains greatly restricted by the toxicity of cytotoxic drugs in normal tissues and cells. Therefore, the development of alternative delivery systems, with few side effects in normal cells, has attracted increasing attention. Energy restriction is a novel and promising approach to cancer treatment, which can restrict tumor growth via inhibition of cellular energy metabolism. In this study, a novel tumor targeting system, based on folate-conjugated bovine serum albumin （BSA）, was developed to co-deliver albendazole and nanosilver simultaneously, to restrain the energy metabolism of tumor cells. This nanosystem showed stronger anti-tumor efficacy than those using nanoparticles without folic acid modification, nanosilver, or albendazole, both in vitro and in vivo. This nanosystem depleted cellular ATP via direct inhibition of glycolytic enzymes and mitochondrial damage, resulting in inhibition of proliferation, cell-cycle arrest, and apoptosis of tumor cells. The enhanced anti-tumor activity contributed to the tumor-targeting ability of this system, resulting in specific energy inhibition in tumor cells. Toxicity evaluation was performed to confirm the safety of this system. This nanosystem provides an efficient and safe strate~ for tumor therapy.